

Walter Ageno

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3316358/walter-ageno-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

489
papers

22,165
citations

63
h-index

138
g-index

522
ext. papers

27,117
ext. citations

6.8
avg, IF

6.73
L-index

#	Paper	IF	Citations
489	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
488	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973	15.1	1682
487	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e443-e885	5.3	1112
486	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020 , 41, 543-603	9.5	1043
485	Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. <i>New England Journal of Medicine</i> , 2008 , 358, 2776-86	59.2	1011
484	Cardiovascular risk factors and venous thromboembolism: a meta-analysis. <i>Circulation</i> , 2008 , 117, 93-102	6.7	674
483	Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. <i>New England Journal of Medicine</i> , 2001 , 345, 165-9	59.2	467
482	Aspirin for preventing the recurrence of venous thromboembolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1959-67	59.2	444
481	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1859-1865	15.4	367
480	Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. <i>Stroke</i> , 2008 , 39, 2249-56	6.7	334
479	Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. <i>Chest</i> , 2006 , 130, 172-5	5.3	313
478	Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. <i>Circulation</i> , 2012 , 126, 2381-91	16.7	307
477	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 429-38	7	273
476	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , 2019 , 20, e566-e581	21.7	264
475	Extended oral anticoagulant therapy after a first episode of pulmonary embolism. <i>Annals of Internal Medicine</i> , 2003 , 139, 19-25	8	261
474	Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4057-62	2.2	261
473	Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. <i>Blood</i> , 2006 , 107, 2766-73	2.2	189

472	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020 , 4, 4693-4738	7.8	187
471	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. <i>Lancet Haematology</i> , 2016 , 3, e12-21	14.6	173
470	Natural history of cerebral vein thrombosis: a systematic review. <i>Blood</i> , 2006 , 108, 1129-34	2.2	169
469	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2020 , 18, 167-169	3.6	168
468	Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. <i>Annals of Internal Medicine</i> , 2009 , 150, 577-85	8	162
467	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. <i>Stroke</i> , 2015 , 46, 2175-82	6.7	157
466	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. <i>Archives of Internal Medicine</i> , 2012 , 172, 1484-91		157
465	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018 , 39, 4208-4218	9.5	156
464	Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 535-48	5.3	155
463	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024	7	147
462	Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. <i>Circulation</i> , 2011 , 124, 824-9	16.7	146
461	Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. <i>Thrombosis Research</i> , 2010 , 125, 518-22	8.2	145
460	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018 , 379, 1118-1127	59.2	143
459	Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 591-9	7	141
458	JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. <i>Blood</i> , 2009 , 113, 5617-23	2.2	141
457	A prospective study on cardiovascular events after acute pulmonary embolism. <i>European Heart Journal</i> , 2005 , 26, 77-83	9.5	135
456	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. <i>JAMA Internal Medicine</i> , 2015 , 175, 1474-80	11.5	131
455	The metabolic syndrome and the risk of venous thrombosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1914-8	15.4	127

454	Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. <i>Thrombosis Research</i> , 2009 , 124, 256-8	8.2	114
453	Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2002 , 137, 251-4	8	114
452	Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. <i>Annals of Internal Medicine</i> , 2009 , 150, 293-300	8	106
451	Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1370-5	15.4	103
450	Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1853-63	15.4	100
449	Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. <i>Blood</i> , 2009 , 114, 952-6	2.2	99
448	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008 , 93, 273-8	6.6	99
447	Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 277-287	35.1	93
446	Epidemiology and risk factors of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 651-8	5.3	92
445	Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 841-4	2.5	91
444	Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. <i>Archives of Internal Medicine</i> , 2002 , 162, 2589-93		90
443	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1297-302	15.4	88
442	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. <i>Internal and Emergency Medicine</i> , 2008 , 3, 117-22	3.7	87
441	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1899-1913	4.5	84
440	Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. <i>Haematologica</i> , 2002 , 87, 746-50; discussion 250	6.6	80
439	Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1176-83	7	79
438	Statins, fibrates, and venous thromboembolism: a meta-analysis. <i>European Heart Journal</i> , 2010 , 31, 1248-56	5.6	78
437	Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 675-82	7	73

436	Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1269-78	15.4	71
435	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 172-9	7	70
434	Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1982-9	15.4	69
433	Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3607-12	2.2	67
432	D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 582-9	15.4	67
431	Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 270-81	15.4	67
430	Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 1055-62	7	66
429	Seasonal and monthly variability in the incidence of venous thromboembolism. A systematic review and a meta-analysis of the literature. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 439-47	7	65
428	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020 , 82, 38-47	3.9	64
427	Statin treatment and the risk of recurrent pulmonary embolism. <i>European Heart Journal</i> , 2013 , 34, 1800-6.5	6.5	63
426	The MASTER registry on venous thromboembolism: description of the study cohort. <i>Thrombosis Research</i> , 2008 , 121, 605-10	8.2	62
425	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 129-43	5.1	60
424	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	60
423	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1010-8	15.4	60
422	Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 399-405	7	58
421	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020 , 41, 509-518	9.5	57
420	Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 511-21	7	56
419	Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 794-800	7	54

418	Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular Diseases</i> , 2009 , 28, 119-23	3.2	54
417	How I treat splanchnic vein thrombosis. <i>Blood</i> , 2014 , 124, 3685-91	2.2	53
416	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008 , 135, 705-6	1.5	53
415	Metabolic syndrome is associated with venous thromboembolism in the Korean population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 311-5	9.4	52
414	A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 849-852	7	52
413	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 1240-8	7	52
412	ABO blood group and vascular disease: an update. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 49-59	9.3	51
411	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. <i>American Journal of Hematology</i> , 2009 , 84, 584-8	7.1	51
410	Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. <i>Thrombosis Research</i> , 2003 , 112, 203-7	8.2	51
409	Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. <i>American Journal of Cardiology</i> , 2001 , 88, 40-4	3	51
408	Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. <i>Blood Transfusion</i> , 2011 , 9, 148-55	3.6	51
407	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. <i>Thrombosis Research</i> , 2015 , 135, 923-32	8.2	50
406	Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 501-4	7	50
405	Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	49
404	The metabolic syndrome as a risk factor for venous and arterial thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 451-7	5.3	49
403	Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 891-7	15.4	49
402	Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1081-3	15.4	48
401	Venous thromboembolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1219-1229	7	47

400	Clinical approach to splanchnic vein thrombosis: risk factors and treatment. <i>Thrombosis Research</i> , 2012 , 130 Suppl 1, S1-3	8.2	46
399	Relationship between ABO blood group and hemorrhage: a systematic literature review and meta-analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 72-82	5.3	46
398	Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. <i>Journal of Infection</i> , 2020 , 81, e75-e78	18.9	45
397	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1054-1065	7	45
396	Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 290-297	7	44
395	Exaggerated initial response to warfarin following heart valve replacement. <i>American Journal of Cardiology</i> , 1999 , 84, 905-8	3	43
394	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 319-327	7	43
393	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015 , 135, 666-72	8.2	42
392	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. <i>Thrombosis Research</i> , 2005 , 116, 301-6	8.2	42
391	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016 , 3, e228-36	14.6	41
390	Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. <i>Cerebrovascular Diseases</i> , 2011 , 31, 109-16	3.2	41
389	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017 , 12, 387-406	3.7	40
388	Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 2478-85	9.4	40
387	A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. <i>Thrombosis Research</i> , 1998 , 91, 237-40	8.2	40
386	The coagulation system in endocrine disorders: a narrative review. <i>Internal and Emergency Medicine</i> , 2007 , 2, 76-83	3.7	40
385	Interventional treatment of venous thromboembolism: a review. <i>Thrombosis Research</i> , 2012 , 129, 418-25	5.2	39
384	Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 271-6	7	38
383	Gender differences in patients with acute ischemic stroke. <i>Women's Health</i> , 2010 , 6, 51-7	3	38

382	The role of thrombolytic therapy in pulmonary embolism. <i>Blood</i> , 2015 , 125, 2191-9	2.2	37
381	Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. <i>Pharmacotherapy</i> , 2008 , 28, 960-7	5.8	37
380	Chronobiology of acute aortic rupture or dissection: a systematic review and a meta-analysis of the literature. <i>Chronobiology International</i> , 2015 , 32, 385-94	3.6	36
379	Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 99-105	5.3	36
378	Brand name versus generic warfarin: a systematic review of the literature. <i>Pharmacotherapy</i> , 2011 , 31, 386-93	5.8	36
377	Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. <i>Thrombosis Research</i> , 2008 , 121, 751-6	8.2	36
376	Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1003-1010	7	36
375	Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1172-1179	7	36
374	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016 , 3, e267-75	14.6	36
373	Is diabetes a hypercoagulable state? A critical appraisal. <i>Acta Diabetologica</i> , 2015 , 52, 1007-16	3.9	35
372	Warfarin interactions with antibiotics in the ambulatory care setting. <i>JAMA Internal Medicine</i> , 2014 , 174, 409-16	11.5	35
371	Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. <i>Haematologica</i> , 2010 , 95, 1587-93	6.6	35
370	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018 , 16, 462-470	3.6	35
369	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018 , 7, e010133	6	35
368	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 176	4.2	34
367	Retrievable vena cava filters: a review. <i>Current Opinion in Hematology</i> , 2006 , 13, 351-6	3.3	34
366	Home-treatment of deep vein thrombosis in patients with cancer. <i>Haematologica</i> , 2005 , 90, 220-4	6.6	34
365	Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. <i>Thrombosis Research</i> , 2014 , 134, 41-3	8.2	33

364	Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). <i>Thrombosis Research</i> , 2013 , 131, 12-6	8.2	32
363	The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury: a prospective cohort study. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 34-8	7	32
362	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019 , 50, 2168-2174	6.7	31
361	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 410-6	7	31
360	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 33-42	35.1	31
359	Splanchnic Vein Thrombosis: Current Perspectives. <i>Vascular Health and Risk Management</i> , 2019 , 15, 449-461	46.1	30
358	Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. <i>Thrombosis Research</i> , 2013 , 132, 770-5	8.2	30
357	In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 893-901	7	30
356	Hospital-based use of thromboprophylaxis in patients with COVID-19. <i>Lancet, The</i> , 2020 , 395, e75	40	29
355	Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 231-46	7	29
354	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 118-21	7	29
353	Subclinical hypothyroidism and deep venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 803-806	7	29
352	A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 732-3	15.1	29
351	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 982-991	7	29
350	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study. <i>Stroke</i> , 2017 , 48, 726-732	6.7	28
349	Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. <i>Circulation</i> , 2014 , 129, 497-503	16.7	28
348	Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. <i>Thrombosis Research</i> , 2010 , 125, 137-41	8.2	28
347	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. <i>Atherosclerosis</i> , 2010 , 212, 564-6	3.1	28

346	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016 , 263, 231-237	5.5	27
345	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. <i>Internal and Emergency Medicine</i> , 2012 , 7, 9-13	3.7	27
344	Retrievable vena cava filters: a clinical review. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 33, 258-66	5.1	27
343	Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 424-32	7	26
342	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. <i>Thrombosis Journal</i> , 2014 , 12, 16	5.6	26
341	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. <i>Internal and Emergency Medicine</i> , 2013 , 8, 735-40	3.7	26
340	Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. <i>Thrombosis Research</i> , 2012 , 130, 369-73	8.2	25
339	Higher mortality rate in patients hospitalised for acute pulmonary embolism during weekends. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 83-9	7	25
338	Seasonal variation in the occurrence of venous thromboembolism: data from the MASTER Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 309-15	3.3	25
337	Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSCA (Italian Federation of Anticoagulation Clinics). <i>Thrombosis and Haemostasis</i> , 2012 , 107, 1100-6	7	25
336	Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. <i>Thrombosis Research</i> , 2017 , 153, 97-100	8.2	24
335	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
334	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. <i>Thrombosis Research</i> , 2018 , 165, 33-37	8.2	24
333	Nonadherence with INR monitoring and anticoagulant complications. <i>Thrombosis Research</i> , 2013 , 132, e124-30	8.2	24
332	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 1027-34	7	24
331	D-dimer is not a long-term prognostic marker following acute cerebral ischemia. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 303-6	1	24
330	The safety of antithrombotic therapy during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2004 , 3, 113-118	4.1	24
329	Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. <i>Drug Safety</i> , 2016 , 39, 1175-1187	5.1	24

328	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. <i>Thrombosis Research</i> , 2015 , 136, 1040-4	8.2	23
327	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 3140-3147	15.1	23
326	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2018 , 164, 69-74	8.2	23
325	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. <i>American Journal of Hematology</i> , 2012 , 87, 384-7	7.1	23
324	Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 167-9	7	23
323	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 65-71	5.1	23
322	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016 , 3, e437-45	14.6	23
321	Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 178-87	5.3	22
320	Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2009 , 4, 123-8	3.7	22
319	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 747-53	7	21
318	Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 363-70	7	21
317	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 616-624 ⁷		21
316	Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. <i>Haematologica</i> , 2002 , 87, 286-91	6.6	21
315	Association between in-hospital mortality and renal dysfunction in 186,219 patients hospitalized for acute stroke in the Emilia-Romagna region of Italy. <i>Angiology</i> , 2014 , 65, 906-10	2.1	20
314	Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. <i>Vascular Medicine</i> , 2017 , 22, 518-524	3.3	20
313	Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. <i>Thrombosis Research</i> , 2013 , 131, 17-23	8.2	20
312	Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice. <i>Thrombosis Research</i> , 2010 , 125, 134-6	8.2	20
311	Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1562-1568	15.4	20

310	Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism. <i>Journal of Clinical Epidemiology</i> , 2018 , 97, 1-13	5.7	19
309	JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. <i>Leukemia Research</i> , 2009 , 33, e212-3	2.7	19
308	Thromboprophylaxis in surgical and medical patients. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 163-75	3.9	19
307	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 663-7	1	19
306	Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 181-183	7	19
305	Venous thrombosis at unusual sites and the role of thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 582-7	5.3	19
304	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
303	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1365-1372	7	18
302	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018 , 162, 7-14	8.2	18
301	Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. <i>Internal and Emergency Medicine</i> , 2015 , 10, 507-14	3.7	18
300	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1051-1058	3.7	18
299	The prevention and treatment of venous thromboembolism in pregnancy. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 397-402	2.5	17
298	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1694-1706	15.4	17
297	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2093-2100	6.7	17
296	Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature. <i>Internal and Emergency Medicine</i> , 2018 , 13, 603-608	3.7	17
295	Splanchnic vein thrombosis: new risk factors and management. <i>Thrombosis Research</i> , 2012 , 129 Suppl 1, S93-6	8.2	17
294	Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009 , 137, 91-3	1.5	17
293	New direct thrombin inhibitors. <i>Internal and Emergency Medicine</i> , 2009 , 4, 479-84	3.7	17

292	Cerebral vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010 , 5, 27-32	3.7	17
291	A survey of thromboprophylaxis management in patients with major trauma. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005 , 34, 249-54		17
290	Statins for acute ischemic stroke. <i>The Cochrane Library</i> , 2011 , CD007551	5.2	16
289	Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISIT). <i>Thrombosis Research</i> , 2009 , 124, e26-31	8.2	16
288	Residual venous obstruction in patients with a single episode of deep vein thrombosis and in patients with recurrent deep vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2005 , 94, 93-5	7	16
287	Practical management of coagulopathy associated with warfarin. <i>BMJ, The</i> , 2010 , 340, c1813	5.9	16
286	Hypercoagulopathy in Severe COVID-19: Implications for Acute Care. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1654-1667	7	16
285	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021 , 16, 1005-1015	3.7	16
284	Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 26	2.3	16
283	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 267-277	5.1	15
282	Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. <i>British Journal of Haematology</i> , 2018 , 183, 457-465	4.5	15
281	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1675-1685	7	15
280	Evidence and clinical judgment: Treatment of cerebral vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1109-15	7	15
279	Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	14
278	Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses. <i>Thrombosis Research</i> , 2018 , 163, 252-259	8.2	14
277	Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. <i>Internal and Emergency Medicine</i> , 2014 , 9, 375-84	3.7	14
276	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1325-1332	4	14
275	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1317-1325	7	14

274	Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 569-76	2.5	14
273	Seasonal variability of venous thromboembolism. <i>Current Opinion in Pulmonary Medicine</i> , 2009 , 15, 403-73		14
272	Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. <i>Thrombosis Research</i> , 2008 , 123, 67-71	8.2	14
271	A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 241-4	7	14
270	Venous and arterial thrombosis in patients with HIV infection. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 259-63	1	14
269	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021 , 385, 2161-2172	59.2	14
268	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016 , 6, e010569	3	14
267	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. <i>TH Open</i> , 2017 , 1, e33-e42	2.7	13
266	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019 , 176, 125-132	8.2	13
265	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2014 , 133, 1052-5	8.2	13
264	Clinical management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 655-67	4.7	13
263	Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 734-40	7	13
262	Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 1287-9	7	13
261	Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. <i>Internal and Emergency Medicine</i> , 2010 , 5, 33-40	3.7	13
260	Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 18, 199-203	5.1	13
259	The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2020 , 15, 447-452	3.7	13
258	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. <i>Lancet Haematology</i> , 2018 , 5, e441-e449	14.6	13
257	Body mass index is associated with the development of the post-thrombotic syndrome. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 305-9	7	13

256	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019 , 14, e0216831	3.7	12
255	Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection. <i>Annals of Hematology</i> , 2020 , 99, 1951-1952	3	12
254	Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 42-54	5.3	12
253	Pharmacological prophylaxis of venous thromboembolism during acute phase of spontaneous intracerebral hemorrhage: what do we know about risks and benefits?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012 , 18, 393-402	3.3	12
252	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009 , 84, 579-83	7.1	12
251	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). <i>Thrombosis Research</i> , 2009 , 124, e1-5	8.2	12
250	The 8th American College of Chest Physicians Guidelines: A perspective on venous thromboembolism guidelines. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 31-35	7	12
249	Metabolic syndrome as a risk factor for deep vein thrombosis after acute cardiac conditions. <i>Thrombosis Research</i> , 2007 , 120, 815-8	8.2	12
248	Update on the diagnosis and management of pulmonary embolism. <i>British Journal of Haematology</i> , 2005 , 131, 301-12	4.5	12
247	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 415-427	7	11
246	Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. <i>Journal of Clinical Pathology</i> , 2018 , 71, 1015-1022	3.9	11
245	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. <i>TH Open</i> , 2019 , 3, e85-e93	2.7	11
244	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 978-80	7	11
243	Natural history of cerebral vein thrombosis. <i>Current Opinion in Pulmonary Medicine</i> , 2007 , 13, 372-6	3	11
242	Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2001 , 12, 225-30	5.1	11
241	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017 , 120, 206-218	10.2	10
240	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020 , 191, 103-112	8.2	10
239	Optimal treatment duration of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11 Suppl 1, 151-60	15.4	10

238	Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach. <i>Drugs</i> , 2012 , 72, 1965-75	12.1	10
237	Treatment of venous thromboembolism. <i>Thrombosis Research</i> , 2000 , 97, V63-72	8.2	10
236	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. <i>Blood</i> , 2021 , 137, 1233-1240	2.2	10
235	Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 867-876	7	10
234	Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1177-1185	4	10
233	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017 , 249, 249-256	3.2	9
232	Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	9
231	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. <i>Thrombosis Research</i> , 2014 , 134, 264-7	8.2	9
230	The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature. <i>Thrombosis Research</i> , 2014 , 134, 84-9	8.2	9
229	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 620217	2	9
228	Evidence and clinical judgment: vena cava filters. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 618-24	7	9
227	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 1091-8	7	9
226	Unusual site thrombosis. <i>Seminars in Hematology</i> , 2011 , 48, 264-70	4	9
225	Recent advances in the management of venous thromboembolism. <i>The Korean Journal of Hematology</i> , 2010 , 45, 8-13		9
224	Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. <i>British Journal of Haematology</i> , 2008 , 143, 284-7	4.5	9
223	Prevention of in-hospital VTE: why can't we do better?. <i>Lancet, The</i> , 2008 , 371, 361-2	40	9
222	Tailoring warfarin induction doses to reflect individual and disease-specific factors. <i>American Journal of Medicine</i> , 2005 , 118, 143-4	2.4	9
221	Managing oral anticoagulant therapy in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Italian physicians. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 623-8	1	9

220	D-dimer testing in ischemic stroke and cerebral sinus and venous thrombosis. <i>Seminars in Vascular Medicine</i> , 2005 , 5, 379-86		9
219	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021 , 8, 639970	4.9	9
218	Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis. <i>Brain and Behavior</i> , 2020 , 10, e01638	3.4	9
217	Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19. <i>Internal and Emergency Medicine</i> , 2021 , 16, 989-996	3.7	9
216	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. <i>Thrombosis Research</i> , 2017 , 154, 64-72	8.2	8
215	Pulmonary embolism prognostic factors and length of hospital stay: A cohort study. <i>Thrombosis Research</i> , 2017 , 156, 155-159	8.2	8
214	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019 , 183, 28-32	8.2	8
213	D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants. <i>PLoS ONE</i> , 2019 , 14, e0219751	3.7	8
212	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013 , 8, 575-80	3.7	8
211	Chronobiologic Aspects of Venous Thromboembolism. <i>Heart Failure Clinics</i> , 2017 , 13, 691-696	3.3	8
210	ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. <i>European Heart Journal Supplements</i> , 2017 , 19, D309-D332	1.5	8
209	Is there a role for timely diagnosis and early anticoagulant treatment of portal vein thrombosis in patients with liver cirrhosis?. <i>Internal and Emergency Medicine</i> , 2008 , 3, 195-6	3.7	8
208	Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety. <i>Current Drug Safety</i> , 2007 , 2, 155-61	1.4	8
207	Weight gain after acute deep venous thrombosis: a prospective observational study. <i>Thrombosis Research</i> , 2003 , 109, 31-5	8.2	8
206	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , 2020 , 133, 936-945	2.4	8
205	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020 , 7, e746-e755	14.6	8
204	Management of recurrent venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S128-31	8.2	8
203	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. <i>Thrombosis Research</i> , 2017 , 155, 23-27	8.2	7

202	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 90-8	5.1	7
201	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2425-2434	7.34	7
200	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2406-2414	7	7
199	The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study). <i>American Journal of Hematology</i> , 2012 , 87, 713-5	7.1	7
198	Venous thrombosis at unusual site in women. <i>Thrombosis Research</i> , 2011 , 127 Suppl 3, S86-8	8.2	7
197	Low levels of low-density lipoprotein cholesterol increase hemorrhagic transformation but not parenchymal hematoma in large artery atherothrombosis. <i>Stroke</i> , 2009 , 40, e544; author reply e545	6.7	7
196	Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 801-3	1	7
195	The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 11-4	1	7
194	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2021	9.5	7
193	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. <i>Internal and Emergency Medicine</i> , 2020 , 15, 453-462	3.7	7
192	Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency. <i>Thrombosis Research</i> , 2020 , 196, 209-212	8.2	7
191	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 1420-1429	8	7
190	Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 181-3	7	7
189	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017 , 34, 620-637	4.1	6
188	Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2013 , 8, 667-72	3.7	6
187	Incidence and diagnosis of pulmonary embolism in Northern Italy: a population-based study. <i>European Journal of Internal Medicine</i> , 2013 , 24, e77-8	3.9	6
186	Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis. <i>Vascular Medicine</i> , 2017 , 22, 529-540	3.3	6
185	Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience. <i>PLoS ONE</i> , 2014 , 9, e97604	3.7	6

184	Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 191-4	7	6
183	Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. <i>Wiener Medizinische Wochenschrift</i> , 2011 , 161, 73-9	2.9	6
182	Managing bleeding complications in patients treated with the old and the new anticoagulants. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3478-82	3.3	6
181	Venous and arterial thrombosis associated with HIV infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 524-9	5.3	6
180	Effect of carotid stenosis on the prognostic value of admission blood pressure in patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2009 , 206, 469-73	3.1	6
179	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. <i>Blood</i> , 2019 , 134, 163-163	2.2	6
178	Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 1192-1202	5.1	6
177	SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. <i>Journal of Medical Virology</i> , 2021 , 93, 5648-5649	19.7	6
176	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016 , 220, 417-28	3.2	6
175	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , 2020 , 4, 1539-1553	7.8	6
174	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021 , 5, e24-e34	3.7	6
173	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. <i>European Journal of Preventive Cardiology</i> , 2021	3.9	6
172	In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 893-901	7.1	6
171	Prestroke CHADS-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 1363-1368	2.8	5
170	Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 336-344	5.1	5
169	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 924-936	7	5
168	Management of incidental splanchnic vein thrombosis in cancer patients. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 318-20	3.1	5
167	Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism?. <i>Internal and Emergency Medicine</i> , 2012 , 7 Suppl 3, S189-92	3.7	5

166	Statins for Acute Ischemic Stroke. <i>Stroke</i> , 2012 , 43,	6.7	5
165	The role of the metabolic syndrome in patients with provoked venous thromboembolic events. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 759-61	7	5
164	Oral Xa inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 727-37, viii-ix	3.1	5
163	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 596-598	7	5
162	The Optimal Duration of Anticoagulant Therapy In Patients with Cancer-Related Deep Vein Thrombosis: The Advantage of Using Residual Vein Thrombosis (the Cancer-DACUS Study). <i>Blood</i> , 2010 , 116, 190-190	2.2	5
161	Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. <i>Blood Transfusion</i> , 2015 , 13, 181-3	3.6	5
160	Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2019 , 17, 229-236	3.6	5
159	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. <i>Blood Transfusion</i> , 2020 , 18, 486-495	3.6	5
158	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , 2020 , 10, e040449	3	5
157	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020 , 3, e2022886	10.4	5
156	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2468-2479	15.4	5
155	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 671-81	5.3	5
154	Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1035-51	3.1	5
153	Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 338-340	5.3	5
152	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021 , 10, 710-712	18.9	5
151	Deep venous thrombosis in the medically ill. <i>Psychophysiology</i> , 2002 , 1, 73-8		5
150	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes. <i>Internal and Emergency Medicine</i> , 2015 , 10, 641-5	3.7	4
149	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018 , 163, 128-131	8.2	4

148	Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2089-2098	15.4	4
147	Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). <i>Patient Preference and Adherence</i> , 2019 , 13, 969-979	2.4	4
146	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. <i>Internal and Emergency Medicine</i> , 2017 , 12, 923-934	3.7	4
145	Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study. <i>Thrombosis Research</i> , 2014 , 134, 1359-62	8.2	4
144	Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 495-505	5.9	4
143	Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 835-7	4	4
142	Clinical trials of deep vein thrombosis prophylaxis in medical patients. <i>Clinical Cornerstone</i> , 2005 , 7, 16-22		4
141	In vitro effects of Apixaban on 5 different cancer cell lines. <i>PLoS ONE</i> , 2017 , 12, e0185035	3.7	4
140	Spotlight on real-world evidence for the treatment of DVT: XALIA. <i>Thrombosis and Haemostasis</i> , 2016 , 116, S41-S49	7	4
139	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 214-219	5.1	4
138	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	4
137	Direct oral anticoagulants for unusual-site venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, 265-277	5.1	4
136	The effect of DOAC-Stop on several oral and parenteral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, O171-O175	2.5	4
135	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. <i>TH Open</i> , 2018 , 2, e139-e146	2.7	4
134	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018 , 269, 75-79	3.2	3
133	Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). <i>Psychology Research and Behavior Management</i> , 2019 , 12, 741-752	3.8	3
132	Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. <i>Internal and Emergency Medicine</i> , 2013 , 8, 689-94	3.7	3
131	Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. <i>Thrombosis Research</i> , 2013 , 131 Suppl 1, S67-70	8.2	3

130	Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 901-9	5.5	3
129	Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study. <i>Haematologica</i> , 2015 , 100, e295-8	6.6	3
128	The effect of subclinical hypothyroidism on vitamin K antagonist treatment. <i>Thrombosis Research</i> , 2012 , 129, 520-2	8.2	3
127	Venous ischemic syndromes. <i>Frontiers of Neurology and Neuroscience</i> , 2012 , 30, 191-4	1.1	3
126	Which patients with unprovoked VTE should receive extended anticoagulation? the minority. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 301-5	5.1	3
125	Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?. <i>Internal and Emergency Medicine</i> , 2009 , 4, 353-4; author reply 355	3.7	3
124	Statins for acute ischemic stroke 2009 ,		3
123	The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. <i>Current Opinion in Anaesthesiology</i> , 2010 , 23, 722-5	2.9	3
122	Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3483-6	3.3	3
121	An unusual case of cerebral vein thrombosis in a patient with giant cell arteritis. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 513-514	7	3
120	Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study. <i>Haematologica</i> , 2007 , 92, 1293-4	6.6	3
119	Prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2006 , 1, 260-2	3.7	3
118	Retrievable vena cava filters: clinical experience. <i>Current Opinion in Internal Medicine</i> , 2006 , 12, 304-9		3
117	Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. the Warfasa STUDY. <i>Blood</i> , 2011 , 118, 543-543	2.2	3
116	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Blood</i> , 2012 , 120, 499-499	2.2	3
115	An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients. <i>Blood</i> , 2017 , 130, 626-626	2.2	3
114	The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis. <i>Blood</i> , 2017 , 130, 627-627	2.2	3
113	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2021 , 19, 14-23	3.6	3

112	Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis. <i>TH Open</i> , 2020 , 4, e224-e230	2.7	3
111	Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 733-741	2.5	3
110	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021 , 201, 63-72	8.2	3
109	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. <i>European Journal of Internal Medicine</i> , 2019 , 61, 29-33	3.9	3
108	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, 326-341	5.1	3
107	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, 426-438	5.1	3
106	Breadth of complications of long-term oral anticoagulant care. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 432-438	3.1	3
105	Incidence Rates and Case-Fatality Rates of Cerebral Vein Thrombosis: A Population-Based Study. <i>Stroke</i> , 2021 , 52, 3578-3585	6.7	3
104	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
103	Direct oral anticoagulants for superficial-vein thrombosis. <i>Lancet Haematology</i> , 2017 , 4, e95-e96	14.6	2
102	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation). <i>European Stroke Journal</i> , 2017 , 2, 46-53	5.6	2
101	Treatment of venous thromboembolism with tinzaparin in oncological patients. <i>Minerva Medica</i> , 2019 , 110, 251-258	2.2	2
100	Managing unusual presentations of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 304-10	5.1	2
99	Sex-related characteristics of cerebral vein thrombosis: A secondary analysis of a multicenter international cohort study. <i>Thrombosis Research</i> , 2020 , 196, 371-374	8.2	2
98	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018 , 2, e1-e7	2.7	2
97	Treating patients with cancer and acute venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 535-43	4	2
96	Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis. <i>European Heart Journal Supplements</i> , 2018 , 20, E6-E11	1.5	2
95	Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. <i>Journal of Translational Internal Medicine</i> , 2018 , 6, 6-10	3	2

94	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019 , 4, 55-64	5.6	2
93	Thromboprophylaxis in acutely ill medical patients: results of a survey among Italian physicians. <i>Thrombosis Research</i> , 2014 , 134, 572-7	8.2	2
92	Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 621-3	7	2
91	Small clots with large impact. <i>Blood</i> , 2015 , 126, 926-7	2.2	2
90	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. <i>Italian Journal of Medicine</i> , 2013 , 7, 8	0.5	2
89	Retinal-vein occlusion. <i>New England Journal of Medicine</i> , 2011 , 364, 979; author reply 979	59.2	2
88	Atypical case of acute coronary syndrome due to coronary-pulmonary steal syndrome secondary to pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2011 , 6, 349-52	3.7	2
87	Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality. <i>Leukemia and Lymphoma</i> , 2008 , 49, 592-5	1.9	2
86	What is the next step in D-dimer research? Education of physicians. <i>Internal and Emergency Medicine</i> , 2006 , 1, 165	3.7	2
85	What's new for DVT prophylaxis for the medically ill. <i>Disease-a-Month</i> , 2005 , 51, 194-9	4.4	2
84	Treatment of venous thromboembolism. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 2, 40-3	2.3	2
83	Low-molecular-weight heparins in the treatment of venous thromboembolism. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000 , 1, 102-105		2
82	Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthroplasty: The RECORD3 Trial.. <i>Blood</i> , 2007 , 110, 308-308	2.2	2
81	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. <i>Blood</i> , 2016 , 128, 1438-1438	2.2	2
80	New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. <i>Cmaj</i> , 2002 , 166, 919-24	3.5	2
79	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021 , 52, 1450-1454	6.7	2
78	Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis. <i>BMC Gastroenterology</i> , 2021 , 21, 253	3	2
77	Cancer-Associated Splanchnic Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 931-943	4.3	2

76	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 5556207	3.7	2
75	In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: a sex effect?. <i>American Journal of Emergency Medicine</i> , 2016 , 34, 665-6	2.9	2
74	Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00026	4.2	2
73	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2021 , 16, 359-368	3.7	2
72	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 983-991	15.4	2
71	Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1009-1013	3.7	2
70	Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1001-1004	3.7	2
69	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2618-2628	15.4	2
68	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021 , 8, e627-e636	14.6	2
67	An unusual case of neck pain in Hashimoto's thyroiditis. <i>Internal and Emergency Medicine</i> , 2017 , 12, 817-819	3.7	1
66	Real life studies and good clinical practice - Authors' reply. <i>Lancet Haematology</i> , 2016 , 3, e160-1	14.6	1
65	Efficacy and safety of patent foramen ovale closure in patients with a cryptogenic stroke: Systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 773-6	7	1
64	New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 571-3	7	1
63	Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. <i>Internal and Emergency Medicine</i> , 2009 , 4, 441-442	3.7	1
62	Unmet clinical needs in the management of patients with splanchnic vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010 , 5, 459-61	3.7	1
61	Statins and secondary prevention of ischemic and hemorrhagic stroke. <i>Stroke</i> , 2008 , 39, e113; author reply e114	6.7	1
60	The Wells rule was not useful in ruling out deep venous thrombosis in a primary care setting. <i>Evidence-Based Medicine</i> , 2006 , 11, 57		1
59	Arterial indications for the low molecular weight heparins. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 233-239		1

58	Cerebral venous thrombosis. <i>Minerva Medica</i> , 2021 ,	2.2	1
57	Treatment of portal vein thrombosis: an updated narrative review. <i>Minerva Medica</i> , 2021 ,	2.2	1
56	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. <i>Blood</i> , 2015 , 126, 894-894	2.2	1
55	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 ,	15.4	1
54	Anticoagulant treatment for Upper Extremity Deep Vein thrombosis: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 ,	15.4	1
53	Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.. <i>Therapeutic Advances in Drug Safety</i> , 2021 , 12, 20420986211062965 ¹	2.5	1
52	Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.. <i>Internal and Emergency Medicine</i> , 2022 , 1	3.7	1
51	Epidemiology of Budd-Chiari Syndrome 2020 , 15-25		1
50	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2020 , 83, 566-575	2.1	1
49	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020 , 5, 374-383 ^{5,6}	5.6	1
48	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 ,	5.3	1
47	Association between body mass index, waist circumference, and relative fat mass with the risk of first unprovoked venous thromboembolism. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 3122-3130	4.5	1
46	Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. <i>Internal and Emergency Medicine</i> , 2016 , 11, 467-76	3.7	1
45	Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives. <i>Hamostaseologie</i> , 2018 , 38, 75-86	1.9	1
44	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021 , 203, 155-162	8.2	1
43	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2801-2813	15.4	1
42	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3031-3043	15.4	1
41	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study.. <i>Stroke</i> , 2022 , 101161STROKEAHA121038239	6.7	1

40	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. <i>Data in Brief</i> , 2017 , 15, 532-539	1.2	○
39	Treatment of pulmonary embolism. <i>Presse Medicale</i> , 2015 , 44, e393-9	2.2	○
38	Patient selection for thromboprophylaxis in medical inpatients. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1639-47	2.5	○
37	Treatment options for deep vein thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1069-75	4	○
36	Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting. <i>Blood</i> , 2013 , 122, 1143-1143	2.2	○
35	Follow-up management of patients receiving direct oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2021 , 16, 571-580	3.7	○
34	Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study. <i>Thrombosis Research</i> , 2021 , 203, 138-141	8.2	○
33	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2772-2780	15.4	○
32	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	○
31	Therapeutic Shifts in the Management of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2012	7	
30	Challenges in patients with splanchnic vein thrombosis. <i>AME Medical Journal</i> , 2017 , 2, 104-104	1	
29	Rivaroxaban: An Evaluation of its Cardiovascular Benefit-Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons. <i>Drugs in R and D</i> , 2015 , 15, 295-306	3.4	
28	Venous thromboembolism: "... an ounce of prevention is worth a pound of cure". <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1174-5	7	
27	Risk factors for venous thromboembolism and prophylaxis in medical inpatients: data from the FADOI GEMINI study. <i>Italian Journal of Medicine</i> , 2013 , 23-31	0.5	
26	How can we improve the diagnosis of deep vein thrombosis and pulmonary embolism at the primary level?. <i>Clinical Practice (London, England)</i> , 2014 , 11, 131-134	3	
25	Steps toward simplifying the treatment of pulmonary embolism. <i>Clinical Practice (London, England)</i> , 2012 , 9, 659-667	3	
24	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Più luci che ombre. <i>Italian Journal of Medicine</i> , 2012 , 6, 153-169	0.5	
23	Venous Thromboembolism: Pathophysiology, Diagnosis, and Prophylaxis 2012 , 306-316		

22	Retinal vein occlusion: time for action has come. <i>Internal and Emergency Medicine</i> , 2011 , 6, 293-5	3.7
21	Fattori di rischio per tromboembolismo venoso e profilassi nei pazienti ricoverati in Medicina Interna: analisi dallo studio FADOI GEMINI <i>Italian Journal of Medicine</i> , 2010 , 4, 23-31	0.5
20	Fluctuations in warfarin dose response after heart valve surgery: implications for cardiac rehabilitation. <i>Monaldi Archives for Chest Disease</i> , 2009 , 72, 29-32	2.7
19	Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2009 , 19, 529-533	2.2
18	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020 , 111, 370-372	2.2
17	Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. <i>Blood Transfusion</i> , 2020 , 18, 386-395	3.6
16	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008-2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2021 , 209, 41-46	8.2
15	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , 2021 , 138, 671-671	2.2
14	Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial. <i>Blood</i> , 2019 , 134, 2441-2441	2.2
13	SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature.. <i>Blood</i> , 2010 , 116, 1113-1113	2.2
12	Statin Treatment Reduces the Incidence of Recurrent Pulmonary Embolism: a Population Based Case-Control Study. <i>Blood</i> , 2010 , 116, 808-808	2.2
11	The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS. <i>Blood</i> , 2010 , 116, 3177-3177	2.2
10	Venous thromboembolism (post-surgery) 2012 , 6-20	
9	Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. <i>Thrombosis Research</i> , 2020 , 196, 21-24	8.2
8	Prediction of venous thromboembolism in patients with lower-limb immobilization. <i>EClinicalMedicine</i> , 2020 , 21, 100285	11.3
7	The Direct Oral Anticoagulants 2016 , 253-268	
6	The safety of anticoagulant therapy in the treatment of splanchnic vein thrombosis associated with acute pancreatitis. <i>Internal and Emergency Medicine</i> , 2020 , 15, 929-931	3.7
5	Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients. <i>Internal and Emergency Medicine</i> , 2021 , 16, 933-939	3.7

- 4 Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. *Journal of Thrombosis and Thrombolysis*, **2021**, 51, 561-570 5.1
- 3 Treatment of Atypical Clots.. *Hamostaseologie*, **2022**, 42, 10-18 1.9
- 2 Applying EBM in Clinical Practice 32-36
- 1 Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results **2022**, 1, 38-44